Skip to main content

Advertisement

Table 2 Hazard ratios of halving of eGFR or ESRD, ESRD, and death for participants with vs. without hematuria according to year of follow-up

From: Hematuria as a risk factor for progression of chronic kidney disease and death: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study

  MODEL 1 MODEL 2 MODEL 3
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Halving of eGFR/ESRD   
 year 1 4.77 (3.15 to 7.25) < 0.001 1.89 (1.24 to 2.87) 0.003 1.74 (1.14 to 2.65) 0.01
 year 2 3.13 (2.37 to 4.13) < 0.001 1.45 (1.09 to 1.92) 0.01 1.38 (1.04 to 1.83) 0.03
 year 3 1.74 (1.29 to 2.34) < 0.001 0.86 (0.63 to 1.16) 0.32 0.82 (0.60 to 1.11) 0.2
 year 4 2.01 (1.46 to 2.77) < 0.001 1.01 (0.73 to 1.41) 0.94 0.99 (0.71 to 1.38) 0.94
 year 5 2.35 (1.65 to 3.36) < 0.001 1.25 (0.87 to 1.79) 0.24 1.22 (0.85 to 1.75) 0.29
 after year 5 1.74 (1.35 to 2.25) < 0.001 1.07 (0.82 to 1.39) 0.63 1.05 (0.81 to 1.37) 0.7
ESRD   
 year 1 6.79 (3.75 to 12.28) < 0.001 2.40 (1.32 to 4.35) 0.004 2.22 (1.22 to 4.04) 0.009
 year 2 3.85 (2.70 to 5.50) < 0.001 1.67 (1.16 to 2.39) 0.005 1.57 (1.09 to 2.26) 0.014
 year 3 1.61 (1.12 to 2.31) 0.01 0.76 (0.52 to 1.09) 0.13 0.73 (0.51 to 1.06) 0.1
 year 4 1.62 (1.15 to 2.29) 0.006 0.77 (0.54 to 1.10) 0.15 0.75 (0.53 to 1.07) 0.12
 year 5 2.50 (1.73 to 3.63) < 0.001 1.19 (0.81 to 1.74) 0.37 1.19 (0.81 to 1.74) 0.38
 after year 5 1.76 (1.35 to 2.29) < 0.001 1.04 (0.79 to 1.36) 0.77 1.06 (0.81 to 1.40) 0.67
Death   
 year 1 2.33 (1.36 to 3.97) 0.002 2.02 (1.18 to 3.46) 0.011 1.88 (1.10 to 3.23) 0.021
 year 2 2.07 (1.23 to 3.47) 0.006 1.88 (1.11 to 3.16) 0.018 1.75 (1.04 to 2.95) 0.035
 year 3 1.14 (0.65 to 2.02) 0.65 1.07 (0.61 to 1.89) 0.81 1.02 (0.58 to 1.80) 0.95
 year 4 0.70 (0.38 to 1.28) 0.25 0.66 (0.36 to 1.21) 0.18 0.61 (0.33 to 1.11) 0.11
 year 5 1.35 (0.83 to 2.20) 0.23 1.33 (0.81 to 2.17) 0.26 1.19 (0.73 to 1.94) 0.49
 after year 5 1.04 (0.74 to 1.46) 0.84 1.12 (0.79 to 1.58) 0.52 1.01 (0.71 to 1.42) 0.97
  1. Halving of eGFR/ESRD: MODEL 1:unadjusted (p-value for the interaction with time:< 0.001); MODEL 2: adjusted for age, race, sex, education, diabetes, eGFR, albuminuria, systolic blood pressure (p-value for the interaction with time: 0.025); MODEL 3: adjusted for variables from MODEL 2 and BMI, NT-pro-BNP, HbA1c, FGF23, serum albumin (p-value for the interaction with time: 0.0426);
  2. ESRD: MODEL 1: unadjusted (p-value for the interaction with time: < 0.001); MODEL 2: adjusted for age, race, sex, education, diabetes, eGFR, albuminuria, systolic blood pressure (p-value for the interaction with time: 0.001); MODEL 3: adjusted for variables from MODEL 2 and BMI, NT-pro-BNP, FGF23, serum albumin, high-sensitivity CRP (p-value for the interaction with time: 0.0022);
  3. DEATH: MODEL 1: unadjusted (p-value for the interaction with time: 0.019); MODEL 2: adjusted for age, race, sex, education, diabetes, eGFR, albuminuria, systolic blood pressure, abi, smoking, cvd (p-value for the interaction with time: 0.0614); MODEL 3: adjusted for variables from MODEL 2 and NT-pro-BNP, High sensitive troponin T, Calcium, FGF23, high-sensitivity CRP (p-value for the interaction with time: 0.0517)
Back to article page